A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | MicrobiomeTrials
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-05Est. Completion: 2027-04-19
Enrollment target: 160 participants
Locations
SunValley Arthritis Center Ltd., Peoria, Arizona, United States
University of California Medical Center, La Jolla, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
Inland Rheumatology Clinical Trials Incorporated, Upland, California, United States
West Broward Rheumatology Associates, Inc., Tamarac, Florida, United States
Willow Rheumatology and Wellness PLLC, Willowbrook, Illinois, United States
Accurate Clinical Research Inc., Lake Charles, Louisiana, United States
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States
Accurate Clinical Management, Houston, Texas, United States
DM Clinical Research, Tomball, Texas, United States
Tidewater Clinical Research, Chesapeake, Virginia, United States
Rheumatic Disease Center, Glendale, Wisconsin, United States
Centro Medico Arsema, Ciudad Autnoma de Buenos Aires, Buenos Aires, Argentina
Centro de Investigaciones Medicas Mar Del Plata, Mar del Plata, Buenos Aires, Argentina
Other microbiome trials you might be interested in